Martin Friedlander, MD, PhD

Articles by Martin Friedlander, MD, PhD

(Image credit: AdobeStock/©KayExam/peopleimages.com)

A new era for MacTel: Clinicians react to FDA approval of revakinagene taroretcel-lwey

ByMartin Friedlander, MD, PhD,Anat Loewenstein, MD,Mohammad Rafieetary, OD, FAAO,Rishi P. Singh, MD,Sheryl Stevenson

March 10th 2025

Insights shed light on what the approval means for providers and their patients affected by this neurodegenerative retinal disease

Angiogenesis 2025: Encapsulated cell therapy for MacTel shows long-term efficacy in phase 3 trials

ByMartin Friedlander, MD, PhD,Sheryl Stevenson

February 12th 2025

Martin Friedlander, MD, PhD, discusses phase 3 macular telangiectasia findings, highlighting the potential for a decade-long alternative to intravitreal injections.

Latest Updated Articles

A new era for MacTel: Clinicians react to FDA approval of revakinagene taroretcel-lwey
Published: March 10th 2025 | Updated:

Martin Friedlander, MD, PhD

Articles by Martin Friedlander, MD, PhD

A new era for MacTel: Clinicians react to FDA approval of revakinagene taroretcel-lwey

Angiogenesis 2025: Encapsulated cell therapy for MacTel shows long-term efficacy in phase 3 trials

Latest Updated Articles

Trending on Ophthalmology Times - Clinical Insights for Eye Specialists

PolyActiva and RareSight partner to develop treatments for rare pediatric retinal diseases

Kodiak Sciences releases follow-up, 20-week data from APEX study

From then to next: Five decades of transformation in ophthalmology

Opus Genetics has Type B RMAT meeting with FDA for its gene therapy candidate, OPGx-LCA5

Q&A: Advancing a long-acting anti-VEGF candidate: What it means for retinal disease